Background: As hematopoietic stem cell transplant (HSCT) grows in accessibility and utility, it remains imperative to understand outcomes for its recipients. Limited data is available on the comorbid correlations for this steadily increasing patient population. We sought to examine the National Inpatient Sample (NIS) database to describe in-hospital outcomes among patients with known hyperlipidemia who received a HSCT.

Methods: Data were extracted from the NIS Database from 2019 and 2020. The NIS was searched for hospitalizations of all patients greater than 18 years old who had previously received a HSCT and were hospitalized thereafter. We then analyzed the outcomes of these patients with hyperlipidemia. Multivariate logistic regression analysis was used to adjust for confounders; SPSS software was used for statistical analysis. The primary outcome was inpatient mortality and secondary outcomes are listed below.

Results: This study included 8,302 patients who had received a HSCT, of which 2641 (31.8%) were found to have hyperlipidemia. These HSCT recipients had a higher prevalence of obesity (9.8% versus 7.0%, p<0.001), hypertension (38.2% versus 23.7%, p<0.001), smoking (26.8% versus 20.5%, p<0.001), and chronic kidney disease (29.7% versus 21.3%, p<0.001). Multivariate regression demonstrated that recipients of a HSCT with hyperlipidemia had higher inpatient mortality (OR 1.329, CI 1.251-1.413, p<0.001). On secondary analysis, HSCT recipients with hyperlipidemia were found to be more likely to have non-alcoholic fatty liver disease (OR 1.607, CI 1.414-1.826, p<0.001), anemia (OR 1.485, CI 1.456-1.514, p<0.001), thrombocytopenia (OR 1.457, CI 1.407-1.508, p<0.001), hypertension (OR 2.057, CI 1.965-2.152, p<0.001), acute kidney failure (OR 1.550, CI 1.499-1.604, p<0.001), all-cause arrhythmias (OR 1.689, CI 1.590-1.795, p<0.001), pericarditis (OR 1.419, CI 1.300-1.549, p<0.001), sepsis (OR 1.439, CI 1.400-1.479), coagulopathies (OR 1.379, CI 1.299-1.463, p<0.001), chronic pulmonary disease (OR 1.805, CI 1.700-1.916, p<0.001), severe liver disease (OR 1.429, CI 1.335-1.530, p<0.001), and acute heart failure (OR 1.905, CI 1.811-2.003, p<0.001).

Conclusion: In this nationally-representative, population‐based retrospective cohort study, patients with hyperlipidemia who have received a HSCT and were subsequently hospitalized were associated with higher mortality and worse outcomes.

Disclosures

No relevant conflicts of interest to declare.

This content is only available as a PDF.
2024
Sign in via your Institution